Health Canada approves CALQUENCE® (acalabrutinib) for adult patients with previously-treated mantle cell lymphoma (MCL)

Tuesday, October 8, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

References

_______________________

1

AstraZeneca Canada Inc., Calquence® (acalabrutinib), Product Monograph. August 2019.

2

Lymphoma Canada. Non-Hodgkin Lymphoma. NHL Subtypes. Accessed August 2019. Available at: https://www.lymphoma.ca/lymphoma/non-hodgkin-lymphoma/nhl-subtypes#3

3

Covey T, Barf T, Gulrajani M, Krantz F, van Lith B, Bibikova E, et al. Abstract 2596: ACP-196: a novel covalent Bruton's tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients. Cancer Res. 2015;75(15 Supplement):2596.

4

Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):323–32.

5

Harrington BK, Gulrajani M, Covey T, Kaptein A, Van Lith B, Izumi R, et al. ACP-196 is a second generation inhibitor of Bruton tyrosine kinase (BTK) with enhanced target specificity. Blood. 2015;126(23):2908.

6

Cheah CY, Seymour JF, Wang M. Mantle Cell Lymphoma. J Clin Oncol. 2016; 34(11):1256-1269. Accessed August 2019. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26755518



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store